Wide distribution of the serum dehydroepiandrosterone and sex steroid levels in postmenopausal women: Role of the ovary?

Menopause

Volumn 18, Issue 1, 2011, Pages 30-43

  Labrie, Fernand ^a,b   Martel, Céline ^a   Balser, John ^c  

^a Endoceutics Inc   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c Veristat Inc   (United States)

Author keywords

Androgens; Dehydroepiandrosterone; Estrogens; Intracrinology.; Menopause

Indexed keywords

ANDROSTANE 3ALPHA,17BETA DIOL 17 GLUCURONIDE; ANDROSTANE 3ALPHA,17BETA DIOL 3 GLUCURONIDE; ANDROSTANOLONE; ANDROSTENEDIOL; ANDROSTENEDIONE; ANDROSTERONE GLUCURONIDE; ESTRADIOL; ESTRONE; ESTRONE SULFATE; GLUCURONIDE; PRASTERONE; PRASTERONE SULFATE; SEX HORMONE; TESTOSTERONE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HORMONE BLOOD LEVEL; HORMONE DEFICIENCY; HUMAN; MENOPAUSAL SYNDROME; OVARIECTOMY; OVARY FUNCTION; POSTMENOPAUSE; PRASTERONE BLOOD LEVEL; SEX HORMONE BLOOD LEVEL;

ADULT; AGED; ANDROSTANE-3,17-DIOL; ANDROSTENEDIOL; ANDROSTENEDIONE; ANDROSTERONE; DEHYDROEPIANDROSTERONE; DEHYDROEPIANDROSTERONE SULFATE; DIHYDROTESTOSTERONE; ESTRADIOL; ESTRONE; FEMALE; HUMANS; MIDDLE AGED; OVARIECTOMY; OVARY; POSTMENOPAUSE; STATISTICS, NONPARAMETRIC; TESTOSTERONE;

EID: 78651411484     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e3181e195a6     Document Type: Article

References (86)

1. Population Division U.S. Census Bureau. Table 1: annual estimates of the population by sex and five-year age groups for the United States: April 1, 2000, to July 1, 2007. NC-EST2007-01. May 2008. Available at: http:// www.census.gov/NC-EST2007-01.
2. The North American Menopause Society. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 Position Statement of The North American Menopause Society. Menopause 2007;14:357-369.
3. Barbaglia G, Macia F, Comas M, et al. Trends in hormone therapy use before and after publication of the Women's Health Initiative trial: 10 years of follow-up. Menopause 2009;16:1061-1064.
4. Labrie C, Bélanger A, Labrie F. Androgenic activity of dehydroepiandrosterone and androstenedione in the rat ventral prostate. Endocrinology 1988;123:1412-1417.
5. Labrie F. Intracrinology. Mol Cell Endocrinol 1991;78:C113-C118.
6. Labrie F, Luu-The V, Bélanger A, Lin S-X, Simard J, Labrie C. Is DHEA a hormone? Starling review. J Endocrinol 2005;187:169-196.
7. Luu-The V, Labrie F. The intracrine sex steroid biosynthesis pathways. In: Martini L, Chrousos GP, Labrie F, Pacak K, Pfaff DW, eds. Neuroendocrinology, Pathological Situations and Diseases, Progress in Brain Research. Vol 181 (chapter 10). New York: Elsevier, 2010:177-192.
8. Baxendale PM, Reed MJ, James VH. Inability of human endometrium or myometrium to aromatize androstenedione. J Steroid Biochem 1981;14: 305-306.
9. Bulun SE, Lin Z, Imir G, et al. Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment. Pharmacol Rev 2005;57:359-383.
10. Toda K, Simpson ER, Mendelson CR, Shizuta Y, Kilgore MW. Expression of the gene encoding aromatase cytochrome P450 (CYP19) in fetal tissues. Mol Endocrinol 1994;8:210-217.
11. Labrie F, Bélanger A, Bélanger P, et al. Androgen glucuronides, instead of testosterone, as the new markers of androgenic activity in women. J Steroid Biochem Mol Biol 2006;99:182-188.
12. Women's Health Initiative. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321-333.
13. Beral V, Bull D, Reeves G. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 2005;365:1543-1551.
14. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
15. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-427.
16. Riman T, Dickman PW, Nilsson S, et al. Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. J Natl Cancer Inst 2002;94:497-504. (Pubitemid 34411288)
17. Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health (Larchmt) 2006;15:35-44. (Pubitemid 43192860)
18. Hsia J, Langer RD, Manson JE, et al. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med 2006;166:357-365. (Pubitemid 43244325)
19. Pines A, Sturdee DW, MacLennan AH, Schneider HP, Burger H, Fenton A. The heart of the WHI study: time for hormone therapy policies to be revised. Climacteric 2007;10:267-269.
20. Ruttimann J. The menopause brain effect: can hormone therapy help? Endocr News 2008:15-16.
21. Labrie F. Combination of breast cancer prevention with tissue-targeted hormone replacement therapy. In: Pasqualini JR, ed. Breast Cancer- Prognosis, Treatment, and Prevention. 2nd ed. New York: Isoforma Healthcare, 2008:201-252.
22. Pelletier G, Labrie C, Martel C, Labrie F. Chronic administration of dehydroepiandrosterone (DHEA) to female monkey and rat has no effect on mammary gland histology. J Steroid Biochem Mol Biol 2008;108:102-108.
23. Labrie F. Drug insight: breast cancer prevention and tissue-targeted hormone replacement therapy. Nat Clin Pract Endocrinol Metab 2007; 3:584-593.
24. Labrie F. Future perspectives of SERMs used alone and in combination with DHEA. Endocr Relat Cancer 2006;13:335-355.
25. Dimitrakakis C, Zhou J, Wang J, et al. A physiologic role for testosterone in limiting estrogenic stimulation of the breast. Menopause 2003; 10:292-298.
26. Labrie F, Luu-The V, Labrie C, et al. Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev 2003;24:152-182.
27. Labrie F, Archer D, Bouchard C, et al. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy. Menopause 2009;16:907-922.
28. Labrie F, Archer D, Bouchard C, et al. Effect on intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause 2009;16:923-931.
29. Labrie F,Archer D, Bouchard C, et al. Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration. Menopause 2009;16: 897-906.
30. Labrie F, Cusan L, Gomez JL, et al. Corrigendum to: effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women. J Steroid Biochem Mol Biol 2008;112:169.
31. Labrie F, Cusan L, Gomez JL, et al. Effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women. J Steroid Biochem Mol Biol 2008;111:178-194.
32. Labrie F, Belanger A, Belanger P, et al. Metabolism of DHEA in postmenopausal women following percutaneous administration. J Steroid Biochem Mol Biol 2007;103:178-188.
33. Labrie F, Cusan L, Gomez JL, et al. Changes in serum DHEA and eleven of its metabolites during 12-month percutaneous administration of DHEA. J Steroid Biochem Mol Biol 2008;110:1-9.
34. Labrie F, Belanger A, Labrie C, Candas B, Cusan L, Gomez JL. Bioavailability and metabolism of oral and percutaneous dehydroepiandrosterone in postmenopausal women. J Steroid Biochem Mol Biol 2007; 107:57-69. (Pubitemid 47362670)
35. Labrie F, Cusan L, Gomez JL, et al. Comparable amounts of sex steroids are made outside the gonads in men and women: strong lesson for hormone therapy of prostate and breast cancer. J Steroid Biochem Mol Biol 2009;113:52-56.
36. Couzinet B, Meduri G, Lecce MG, et al. The postmenopausal ovary is not a major androgen-producing gland. J Clin Endocrinol Metab 2001;86: 5060-5066.
37. Abraham GE, Lobotsky J, Lloyd CW. Metabolism of testosterone and androstenedione in normal and ovariectomized women. J Clin Invest 1969;48:696-703.
38. Jabara S, Christenson LK, Wang CY, et al. Stromal cells of the human postmenopausal ovary display a distinctive biochemical and molecular phenotype. J Clin Endocrinol Metab 2003;88:484-492.
39. Cauley JA, Gutai JP, Kuller LH, LeDonne D, Powell JG. The epidemiology of serum sex hormones in postmenopausal women. Am J Epidemiol 1989;129:1120-1131.
40. Nagamani M, Urban RJ. Expression of messenger ribonucleic acid encoding steroidogenic enzymes in postmenopausal ovaries. J Soc Gynecol Investig 2003;10:37-40.
41. Havelock JC, Rainey WE, Bradshaw KD, Carr BR. The post-menopausal ovary displays a unique pattern of steroidogenic enzyme expression. Hum Reprod 2006;21:309-317.
42. Judd HL, Lucas WE, Yen SS. Effect of oophorectomy on circulating testosterone and androstenedione levels in patients with endometrial cancer. Am J Obstet Gynecol 1974;118:793-798.
43. Judd HL, Judd GE, Lucas WE, Yen SS. Endocrine function of the postmenopausal ovary: concentration of androgens and estrogens in ovarian and peripheral vein blood. J Clin Endocrinol Metab 1974;39:1020-1024.
44. Fogle RH, Stanczyk FZ, Zhang X, Paulson RJ. Ovarian androgen production in postmenopausal women. J Clin Endocrinol Metab 2007;92: 3040-3043. (Pubitemid 47236368)
45. McShane LM, Dorgan JF, Greenhut S, Damato JJ. Reliability and validity of serum sex hormone measurements. Cancer Epidemiol Biomarkers Prev 1996;5:923-928.
46. Rinaldi S, Dechaud H, Biessy C, et al. Reliability and validity of commercially available, direct radioimmunoassays for measurement of blood androgens and estrogens in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2001;10:757-765.
47. Dowsett M, Folkerd E. Deficits in plasma oestradiol measurement in studies and management of breast cancer. Breast Cancer Res 2005;7:1-4.
48. Spark RF. Dehydroepiandrosterone: a springboard hormone for female sexuality. Fertil Steril 2002;77:S19-S25.
49. Longcope C, Franz C, Morello C, Baker R, Johnston CC Jr. Steroid and gonadotropin levels in women during the peri-menopausal years. Maturitas 1986;8:189-196.
50. Zumoff B, Strain GW, Miller LK, Rosner W. Twenty-four-hour mean plasma testosterone concentration declines with age in normal premenopausal women. J Clin Endocrinol Metab 1995;80:1429-1430.
51. Baker ME. Co-evolution of steroidogenic and steroid-inactivating enzymes and adrenal and sex steroid receptors. Mol Cell Endocrinol 2004;215:55-62.
52. Keshavarz H, Hillis S, Kieke B, Marchbanks P. Healthcare Cost and Utilization Project (HCUP), 1988-2001: a federal-state-industry partnership in health data. July 2003. Rockville, MD: Agency for Healthcare Research and Quality, 2008. Available at: http//:www.cdc.gov/mmwr/ preview/mmwrhtml/ss510al. htm.
53. Melton LJ 3rd, Bergstralh EJ, Malkasian GD, O'Fallon WM. Bilateral oophorectomy trends in Olmsted County, Minnesota, 1950-1987. Epidemiology 1991;2:149-152.
54. Rocca WA, Grossardt BR, de Andrade M, Malkasian GD, Melton LJ 3rd. Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncol 2006;7:821-828.
55. Rivera CM, Grossardt BR, Rhodes DJ, et al. Increased cardiovascular mortality after early bilateral oophorectomy. Menopause 2009;16:15-23.
56. Colditz GA, Willett WC, Stampfer MJ, Rosner B, Speizer FE, Hennekens CH. Menopause and the risk of coronary heart disease in women. N Engl J Med 1987;316:1105-1110.
57. Ossewaarde ME, Bots ML, Verbeek AL, et al. Age at menopause, cause-specific mortality and total life expectancy. Epidemiology 2005; 16:556-562.
58. Falkeborn M, Schairer C, Naessen T, Persson I. Risk of myocardial infarction after oophorectomy and hysterectomy. J Clin Epidemiol 2000;53:832-837.
59. Atsma F, Bartelink ML, Grobbee DE, van der Schouw YT. Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause 2006;13:265-279.
60. Parker WH, Broder MS, Liu Z, Shoupe D, Farquhar C, Berek JS. Ovarian conservation at the time of hysterectomy for benign disease. Obstet Gynecol 2005;106:219-226.
61. Kung HC, Hoyert DL, Xu J, Murphy SL. Deaths: final data for 2005. Natl Vital Stat Rep 2008;56:1-120.
62. Parker WH, Manson JE. Oophorectomy and cardiovascular mortality: is there a link? Menopause 2009;16:1-2.
63. Parker WH, Broder MS, Chang E, et al. Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses' health study. Obstet Gynecol 2009;113:1027-1037.
64. Barrett-Connor E, Khaw KT, Yen SS. A prospective study of dehydroepiandrosterone sulfate, mortality and cardiovascular disease. N Engl J Med 1986;315:1519-1524.
65. Trivedi DP, Khaw KT. Dehydroepiandrosterone sulfate and mortality in elderly men and women. J Clin Endocrinol Metab 2001;86:4171-4177.
66. Maggio M, Lauretani F, Ceda GP, et al. Relationship between low levels of anabolic hormones and 6-year mortality in older men: the Aging in the Chianti Area (InCHIANTI) study. Arch Intern Med 2007;167:2249-2254.
67. Tivesten A, Vandenput L, Labrie F, et al. Low serum testosterone and estradiol predict mortality in elderly men. J Clin Endocrinol Metab 2009;94:2482-2488.
68. Ohlsson C, Labrie F, Barrett-Connor E, et al. Low serum levels of dehydroepiandrosterone Predict all-cause and cardiovascular mortality in elderly Swedish men. J Clin Endocrinol Metab. 2010. In press.
69. Berr C, Lafont S, Debuire B, Dartigues JF, Baulieu EE. Relationships of dehydroepiandrosterone sulfate in the elderly with functional, psychological, and mental status, and short-term mortality: a French communitybased study. Proc Natl Acad Sci USA 1996;93:13410-13415.
70. Mazat L, Lafont S, Berr C, et al. Prospective measurements of dehydroepiandrosterone sulfate in a cohort of elderly subjects: relationship to gender, subjective health, smoking habits, and 10-year mortality. Proc Natl Acad Sci USA 2001;98:8145-8150.
71. Labrie F. DHEA, important source of sex steroids in men and even more in women. In: Martini L, Chrousos GP, Labrie F, Pacak K, Pfaff DW, eds. Neuroendocrinology, the Normal Neuroendocrine System, Progress in Brain Research. Vol 182. New York: Elsevier. In press.
72. Gordon GB, Bush DE, Weisman HF. Reduction of atherosclerosis by administration of dehydroepiandrosterone. A study in the hypercholesterolemic New Zealand White rabbit with aortic intimal injury. J Clin Invest 1988;82:712-720.
73. Arad Y, Badimon JJ, Badimon L, Hembree WC, Ginsberg HN. Dehydroepiandrosterone feeding prevents aortic fatty streak formation and cholesterol accumulation in cholesterol-fed rabbit. Arteriosclerosis 1989;9:159-166.
74. Eich DM, Nestler JE, Johnson DE, et al. Inhibition of accelerated coronary atherosclerosis with dehydroepiandrosterone in the heterotopic rabbit model of cardiac transplantation. Circulation 1993;87:261-269.
75. Alexandersen P, Haarbo J, Byrjalsen I, Lawaetz H, Christiansen C. Natural androgens inhibit male atherosclerosis: a study in castrated, cholesterol-fed rabbits. Circ Res 1999;84:813-819.
76. Yorek MA, Coppey LJ, Gellett JS, et al. Effect of treatment of diabetic rats with dehydroepiandrosterone on vascular and neural function. Am J Physiol Endocrinol Metab 2002;283:E1067-E1075.
77. Liu D, Dillon JS. Dehydroepiandrosterone activates endothelial cell nitric-oxide synthase by a specific plasma membrane receptor coupled to G>i,2.3. J Biol Chem 2002;277:21379-21388.
78. Liu D, Dillon JS. Dehydroepiandrosterone stimulates nitric oxide release in vascular endothelial cells: evidence for a cell surface receptor. Steroids 2004;69:279-289.
79. Simoncini T, Mannella P, Fornari L, Varone G, Caruso A, Genazzani AR. Dehydroepiandrosterone modulates endothelial nitric oxide synthesis via direct genomic and nongenomic mechanisms. Endocrinology 2003;144:3449-3455.
80. Altman R, Motton DD, Kota RS, Rutledge JC. Inhibition of vascular inflammation by dehydroepiandrosterone sulfate in human aortic endothelial cells: roles of PPAR> and NF-JB. Vascul Pharmacol 2008;48:76-84.
81. Dillon JS. Dehydroepiandrosterone, dehydroepiandrosterone sulfate and related steroids: their role in inflammatory, allergic and immunological disorders. Curr Drug Targets Inflamm Allergy 2005;4:377-385.
82. Chen CC, Parker CR Jr. Adrenal androgens and the immune system. Semin Reprod Med 2004;22:369-377.
83. Barkhausen T, Westphal BM, Putz C, Krettek C, van Griensven M. Dehydroepiandrosterone administration modulates endothelial and neutrophil adhesion molecule expression in vitro. Crit Care 2006;10:R109.
84. Gutierrez G, Mendoza C, Zapata E, et al. Dehydroepiandrosterone inhibits the TNF->Yinduced inflammatory response in human umbilical vein endothelial cells. Atherosclerosis 2007;190:90-99.
85. Poynter ME, Daynes RA. Peroxisome proliferator-activated receptor > activation modulates cellular redox status, represses nuclear factor-JB signaling, and reduces inflammatory cytokine production in aging. J Biol Chem 1998;273:32833-32841.
86. Khalil A, Lehoux JG, Wagner RJ, et al. Dehydroepiandrosterone protects low density lipoproteins against peroxidation by free radicals produced by F-radiolysis of ethanol-water mixtures. Atherosclerosis 1998;136:99-107.